It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The recently discovered histone post-translational modification crotonylation connects cellular metabolism to gene regulation. Its regulation and tissue-specific functions are poorly understood. We characterize histone crotonylation in intestinal epithelia and find that histone H3 crotonylation at lysine 18 is a surprisingly abundant modification in the small intestine crypt and colon, and is linked to gene regulation. We show that this modification is highly dynamic and regulated during the cell cycle. We identify class I histone deacetylases, HDAC1, HDAC2, and HDAC3, as major executors of histone decrotonylation. We show that known HDAC inhibitors, including the gut microbiota-derived butyrate, affect histone decrotonylation. Consistent with this, we find that depletion of the gut microbiota leads to a global change in histone crotonylation in the colon. Our results suggest that histone crotonylation connects chromatin to the gut microbiota, at least in part, via short-chain fatty acids and HDACs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Nuclear Dynamics, Babraham Institute, Cambridge, UK
2 Nuclear Dynamics, Babraham Institute, Cambridge, UK; Université Clermont Auvergne, Clermont–Ferrand, France
3 Department of Experimental Oncology, Istituto Europeo di Oncologia, Milano, Italy
4 Laboratory of Immunoinflammation, Institute of Biology, UNICAMP, Campinas, Brazil
5 Department of Pharmaceutical Sciences, Institute of Environmental, Chemistry and Pharmaceutical Sciences, Universidade Federal de São Paulo, Diadema, SP, Brazil; Chemical Biology Graduate Program, Universidade Federal de São Paulo, Diadema, SP, Brazil
6 Department of Pharmaceutical Sciences, Institute of Environmental, Chemistry and Pharmaceutical Sciences, Universidade Federal de São Paulo, Diadema, SP, Brazil
7 Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK
8 Biological Chemistry, Babraham Institute, Cambridge, UK
9 Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK; Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
10 Nuclear Dynamics, Babraham Institute, Cambridge, UK; School of Biological Sciences, University of Essex, Colchester, UK